Pharmacogenomics of Impaired Tyrosine Kinase Inhibitor Response: Lessons Learned From Chronic Myelogenous Leukemia

Area of Science:

• Oncology
• Hematology
• Pharmacology

Background:

• Targeted anti-cancer therapy relies on small molecules, with tyrosine kinase inhibitors (TKIs) pioneering this approach.
• TKIs have been successfully used to treat chronic myelogenous leukemia (CML) since 2001, improving patient survival rates.
• CML is characterized by the BCR-ABL1 fusion gene, a primary target for TKI therapy.

Purpose of the Study:

• To review approved TKIs for CML treatment, including their side effects and limitations.
• To elucidate mechanisms of TKI resistance in CML, encompassing both BCR-ABL1-dependent and independent pathways.
• To provide insights into analyzing TKI resistance and its implications for CML management.

Main Methods:

• Review of approved TKIs for chronic myelogenous leukemia.
• Summary of BCR-ABL1-dependent resistance mechanisms, including clinically observed mutations.
• Discussion of BCR-ABL1-independent resistance mechanisms, such as cytochrome P450 interactions, drug efflux, microRNA deregulation, and alternative signaling pathways.

Main Results:

• TKIs achieve high survival rates in CML patients, but 20-25% experience treatment failure.
• BCR-ABL1 mutations are a key cause of TKI resistance.
• BCR-ABL1-independent mechanisms, including genetic and cellular factors, also contribute significantly to TKI resistance.

Conclusions:

• Understanding TKI resistance mechanisms is crucial for optimizing CML treatment strategies.
• Further research into TKI resistance, including in vitro studies, can guide the development of more effective therapies.
• Addressing both BCR-ABL1-dependent and independent resistance is essential for improving long-term outcomes in CML patients.